CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more
CellaVision AB (CEVI) - Net Assets
Latest net assets as of December 2025: Skr887.58 Million SEK
Based on the latest financial reports, CellaVision AB (CEVI) has net assets worth Skr887.58 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.09 Billion) and total liabilities (Skr207.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr887.58 Million |
| % of Total Assets | 81.07% |
| Annual Growth Rate | 10.91% |
| 5-Year Change | 63.37% |
| 10-Year Change | 330.5% |
| Growth Volatility | 42.35 |
CellaVision AB - Net Assets Trend (2000–2025)
This chart illustrates how CellaVision AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CellaVision AB (2000–2025)
The table below shows the annual net assets of CellaVision AB from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr887.58 Million | +8.81% |
| 2024-12-31 | Skr815.73 Million | +13.87% |
| 2023-12-31 | Skr716.39 Million | +11.65% |
| 2022-12-31 | Skr641.63 Million | +18.10% |
| 2021-12-31 | Skr543.28 Million | +26.46% |
| 2020-12-31 | Skr429.62 Million | +23.32% |
| 2019-12-31 | Skr348.37 Million | +19.97% |
| 2018-12-31 | Skr290.38 Million | +20.56% |
| 2017-12-31 | Skr240.85 Million | +16.82% |
| 2016-12-31 | Skr206.18 Million | +12.35% |
| 2015-12-31 | Skr183.52 Million | +21.30% |
| 2014-12-31 | Skr151.30 Million | +14.17% |
| 2013-12-31 | Skr132.52 Million | +6.09% |
| 2012-12-31 | Skr124.91 Million | -0.92% |
| 2011-12-31 | Skr126.07 Million | +11.15% |
| 2010-12-31 | Skr113.42 Million | +51.64% |
| 2009-12-31 | Skr74.80 Million | +62.66% |
| 2008-12-31 | Skr45.98 Million | +129.10% |
| 2007-12-31 | Skr20.07 Million | +13.19% |
| 2006-12-31 | Skr17.73 Million | -33.24% |
| 2005-12-31 | Skr26.56 Million | +46.36% |
| 2004-12-31 | Skr18.15 Million | +124.91% |
| 2003-12-31 | Skr8.07 Million | -83.42% |
| 2002-12-31 | Skr48.66 Million | -41.09% |
| 2001-12-31 | Skr82.60 Million | +23.90% |
| 2000-12-31 | Skr66.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CellaVision AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr887.58 Million | 100.00% |
| Total Equity | Skr887.58 Million | 100.00% |
CellaVision AB Competitors by Market Cap
The table below lists competitors of CellaVision AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Allied Supreme Corp
TW:4770
|
$262.65 Million |
|
Ningbo Bohui Chemical Technology
SHE:300839
|
$262.66 Million |
|
Lloyds Engineering Works Limited
NSE:LLOYDSENGG
|
$262.66 Million |
|
Cafe24 Corp
KQ:042000
|
$262.68 Million |
|
First Copper Technology Co Ltd
TW:2009
|
$262.55 Million |
|
Satellogic V Inc
NASDAQ:SATL
|
$262.55 Million |
|
Longxing Chemical Stock Co Ltd
SHE:002442
|
$262.50 Million |
|
ShaMaran Petroleum Corp
PINK:SHASF
|
$262.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CellaVision AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 815,726,000 to 887,578,000, a change of 71,852,000 (8.8%).
- Net income of 153,078,000 contributed positively to equity growth.
- Dividend payments of 59,629,000 reduced retained earnings.
- Other comprehensive income decreased equity by 29,733,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr153.08 Million | +17.25% |
| Dividends Paid | Skr59.63 Million | -6.72% |
| Other Comprehensive Income | Skr-29.73 Million | -3.35% |
| Other Changes | Skr8.14 Million | +0.92% |
| Total Change | Skr- | 8.81% |
Book Value vs Market Value Analysis
This analysis compares CellaVision AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 177.54x to 4.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | Skr0.84 | Skr149.40 | x |
| 2008-12-31 | Skr1.93 | Skr149.40 | x |
| 2009-12-31 | Skr3.14 | Skr149.40 | x |
| 2010-12-31 | Skr4.76 | Skr149.40 | x |
| 2011-12-31 | Skr5.29 | Skr149.40 | x |
| 2012-12-31 | Skr5.24 | Skr149.40 | x |
| 2013-12-31 | Skr5.56 | Skr149.40 | x |
| 2014-12-31 | Skr6.34 | Skr149.40 | x |
| 2015-12-31 | Skr7.69 | Skr149.40 | x |
| 2016-12-31 | Skr8.64 | Skr149.40 | x |
| 2017-12-31 | Skr10.10 | Skr149.40 | x |
| 2018-12-31 | Skr12.17 | Skr149.40 | x |
| 2019-12-31 | Skr14.61 | Skr149.40 | x |
| 2020-12-31 | Skr18.01 | Skr149.40 | x |
| 2021-12-31 | Skr22.78 | Skr149.40 | x |
| 2022-12-31 | Skr26.90 | Skr149.40 | x |
| 2023-12-31 | Skr30.03 | Skr149.40 | x |
| 2024-12-31 | Skr34.20 | Skr149.40 | x |
| 2025-12-31 | Skr37.21 | Skr149.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CellaVision AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.25%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.17%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.23x
- Recent ROE (17.25%) is below the historical average (23.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 13.08% | 3.52% | 1.69x | 2.20x | Skr617.80K |
| 2008 | 54.48% | 24.94% | 1.04x | 2.10x | Skr20.46 Million |
| 2009 | 37.06% | 25.44% | 0.96x | 1.52x | Skr20.24 Million |
| 2010 | 33.81% | 29.13% | 0.81x | 1.43x | Skr27.01 Million |
| 2011 | 11.61% | 9.42% | 0.87x | 1.42x | Skr2.03 Million |
| 2012 | 5.16% | 3.81% | 0.95x | 1.43x | Skr-6.04 Million |
| 2013 | 14.29% | 10.53% | 0.95x | 1.42x | Skr5.68 Million |
| 2014 | 20.80% | 14.51% | 1.07x | 1.34x | Skr16.34 Million |
| 2015 | 28.78% | 22.07% | 1.09x | 1.20x | Skr34.47 Million |
| 2016 | 29.00% | 22.56% | 1.03x | 1.24x | Skr39.18 Million |
| 2017 | 28.95% | 22.54% | 1.03x | 1.25x | Skr45.64 Million |
| 2018 | 30.54% | 24.31% | 0.98x | 1.28x | Skr59.65 Million |
| 2019 | 28.47% | 21.48% | 0.72x | 1.84x | Skr64.33 Million |
| 2020 | 20.83% | 18.98% | 0.71x | 1.55x | Skr46.52 Million |
| 2021 | 23.07% | 22.16% | 0.69x | 1.52x | Skr71.01 Million |
| 2022 | 18.44% | 18.51% | 0.72x | 1.39x | Skr54.17 Million |
| 2023 | 18.19% | 19.24% | 0.73x | 1.30x | Skr58.67 Million |
| 2024 | 17.25% | 19.46% | 0.71x | 1.24x | Skr59.15 Million |
| 2025 | 17.25% | 20.17% | 0.69x | 1.23x | Skr64.32 Million |
Industry Comparison
This section compares CellaVision AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $81,325,362
- Average return on equity (ROE) among peers: -84.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CellaVision AB (CEVI) | Skr887.58 Million | 13.08% | 0.23x | $262.59 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |